Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
No biomarker
Cancer:
Waldenstrom Macroglobulinemia
Regimen:
BDR (bortezomib + dexamethasone injection + Rituxan (rituximab))
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
NCCN
Excerpt:
Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma: PRIMARY THERAPY FOR WM/LPL...Preferred Regimens...Bortezomib/dexamethasone/rituximab
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login